CN103442719A - Aqueous solution containing hyaluronic acid or salt thereof - Google Patents
Aqueous solution containing hyaluronic acid or salt thereof Download PDFInfo
- Publication number
- CN103442719A CN103442719A CN2012800110602A CN201280011060A CN103442719A CN 103442719 A CN103442719 A CN 103442719A CN 2012800110602 A CN2012800110602 A CN 2012800110602A CN 201280011060 A CN201280011060 A CN 201280011060A CN 103442719 A CN103442719 A CN 103442719A
- Authority
- CN
- China
- Prior art keywords
- hyaluronate
- aqueous solution
- hyaluronic acid
- ferrum
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Abstract
The present invention reveals a highly stable aqueous solution containing hyaluronic acid or a salt thereof, wherein the divalent soluble iron content is no greater than 5 ppb, the aqueous solution comprises a compound comprising iodine as a reducing agent; the reducing agent is a metal iodide compound; and the concentration of the hyaluronic acid or a the salt thereof is 5-15 mg/mL.
Description
Technical field
The present invention relates to the aqueous solution containing hyaluronic acid (hyaluronic acid) or hyaluronate, the containing ratio of described hyaluronic divalent dissolubility ferrum is low, and has the reducing agent that contains iodine.
Background technology
The disaccharide unit that known hyaluronic acid refers to N-acetyl-glucosamine and glucuronic acid in conjunction with and the polysaccharide that forms.Hyaluronic acid can be used as the raw material of pharmaceuticals, cosmetics, food etc. usually.As hyaluronic production method, the method for being manufactured from the extract of the cockscomb of chicken etc. that is used to is arranged, or, utilize the method for being produced with the fermentation method of microorganism.
For example, put down in writing use streptococcus zooepidemicus (Streptococcus zooepidemicus) in patent documentation 1, utilized fermentation method to produce hyaluronic acid.Be logged in this patent documentation 1, add ferrous sulfate so that concentration while becoming its concentration of 3 times (embodiment 3) in cultivation, hyaluronic yield and the molecular weight of (embodiment 1) can increase when not adding.
In addition, in patent documentation 2, be logged into, use streptococcus equi (Streptococcus equi) (ATCC9527) to utilize fermentation method to produce hyaluronic acid powder.Record experimental data in patent documentation 3, it has shown in the hyaluronate sodium crystallization that the method based on patent documentation 2 is produced and has contained in a large number calcium, magnesium and ferrum.In addition, in patent documentation 3, be logged into, the hyaluronic acid obtained by the method made based on patent documentation 2 contains liquid and further contacts with chelating resin, thereby the containing ratio that obtains calcium, magnesium and ferrum is reduced to the hyaluronate sodium crystallization lower than 10ppm.
The look-ahead technique document
Patent documentation
The flat 9-56394 of patent documentation 1 Japanese Patent Application Laid-Open
Patent documentation 3 Japanese Patent Application Laid-Open 2008-280430
Summary of the invention
Invent problem to be solved
Yet the prior art of above-mentioned document record has room for improvement in the following areas.
First: in the production method of patent documentation 1, due in culture medium a large amount of add ferrous sulfate (iron sulfate (II), FeSO4), so think after refining contain hyaluronic solution in be easy to sneak into ferrum.In addition, in order to remove de-iron the culture medium from containing in a large number ferrous sulfate, need more than ever before cost.
Second: in the production method of patent documentation 2, contain in a large number calcium, magnesium and ferrum in hyaluronic acid powder, the purity of hyaluronate sodium is low.
The 3rd: be logged in the production method of patent documentation 3, the containing ratio of calcium, magnesium and ferrum in the hyaluronate sodium crystallization is reduced to lower than 10ppm, still, concrete containing ratio is how many and is indefinite.In addition, its analysis result is the ppm degree, the elaboration shortcoming.In addition, specifically obtain the also not record of what kind of effect by the containing ratio that reduces calcium, magnesium and ferrum.
The present invention In view of the foregoing completes, and its purpose is to provide the aqueous solution containing hyaluronic acid or hyaluronate, and in described hyaluronic acid, the containing ratio of the dissolubility ferrum of divalent is below 5ppb, and has the reducing agent that contains iodine, and therefore, its stability is high.
The technological means of dealing with problems
The inventor etc. are studied the contained impurity of aqueous solution containing hyaluronic acid or hyaluronate, and result finds that the stability of the higher hyaluronan molecule of containing ratio of the divalent dissolubility ferrum of sneaking in the hyaluronic acid saline solution more reduces first.In addition, even also the containing ratio of the dissolubility ferrum of surprised discovery 3 valencys is large for the inventor etc., the stability of hyaluronan molecule can not reduce yet, the phenomenon of only having the stability that causes hyaluronan molecule in the situation that the containing ratio of dissolubility ferrum of divalent is large to reduce.
Therefore, in the containing ratio of the dissolubility ferrum of the divalent that the inventor etc. sneak in the aqueous solution reduced containing hyaluronic acid or hyaluronate, seek the additive that the stability that can suppress the hyaluronan molecule that the dissolubility ferrum by divalent causes reduces, result is found the reducing agent that contains iodine by interpolation first, thereby can suppress the phenomenon that the stability of the hyaluronan molecule that the dissolubility ferrum because of divalent causes reduces.In addition, even the inventor etc. also the compound of surprised discovery reproducibility also when adding sodium bromide, sodium sulfite, sodium sulfide, sodium thioglycolate, glucose and ascorbic acid, also can't suppress the reduction of the stability of the hyaluronan molecule that the dissolubility ferrum because of divalent causes, on the contrary, the situation that reduces stability because of interpolation is more, thereby completes the present invention.
That is, according to the present invention, the containing ratio that the dissolubility ferrum of divalent is provided is below 5ppb, and has the aqueous solution containing hyaluronic acid or hyaluronate of the reducing agent that contains iodine.Should be containing the aqueous solution of hyaluronic acid or hyaluronate, the intrinsic viscosity after preservation (limiting viscosity) residual rate is good, and this is confirmed in embodiment described later.Therefore, be suitable for the raw material of pharmaceuticals, cosmetics, food etc.
In addition, according to the present invention, provide the medical composition that comprises the aqueous solution that contains above-mentioned hyaluronic acid or hyaluronate.This medical composition comprises the good aqueous solution containing hyaluronic acid or hyaluronate of intrinsic viscosity residual rate after preservation.Therefore, be difficult for occurring the reduced viscosity or the quality reduction that produce along with time lapse.
In addition, according to the present invention, provide the arthrosis treatment that comprises the aqueous solution that contains above-mentioned hyaluronic acid or hyaluronate injection.The treatment of this arthrosis comprises the good aqueous solution containing hyaluronic acid or hyaluronate of intrinsic viscosity residual rate after preservation with injection.Therefore, in the situation that intraarticular or its periphery are thrown to medicament, obtain good anelasticity.
In addition, according to the present invention, provide a kind of cosmetic composition that comprises the aqueous solution that contains above-mentioned hyaluronic acid or hyaluronate.This cosmetic composition comprises the good aqueous solution containing hyaluronic acid or hyaluronate of intrinsic viscosity residual rate after preservation.Therefore, be difficult for occurring the reduced viscosity or the quality reduction that produce along with time lapse.
In addition, according to the present invention, a kind of production method of the aqueous solution containing hyaluronic acid or hyaluronate is provided, this production method comprises: the compositions that will contain the dissolubility ferrum of hyaluronic acid or hyaluronate and divalent is dissolved in the operation in aqueous solution with the reducing agent that contains iodine, when the mode that becomes 10mg/mL with the concentration of hyaluronic acid or hyaluronate is dissolved in aqueous solution, the containing ratio of the dissolubility ferrum of the divalent in the aqueous solution of above-mentioned composition is below 5ppb.According to this production method, can produce good hyaluronic acid or the hyaluronate of intrinsic viscosity residual rate after preservation.
In addition, according to the present invention, a kind of stabilisation promotion method of the aqueous solution containing hyaluronic acid or hyaluronate is provided, described method comprises: compositions and the reducing agent that contains iodine that will contain the dissolubility ferrum of hyaluronic acid or hyaluronate and divalent are dissolved in the operation in aqueous solution, and above-mentioned composition take that mode that the concentration of hyaluronic acid or hyaluronate becomes 10mg/mL is while being dissolved in aqueous solution, the containing ratio of the dissolubility ferrum of divalent in aqueous solution is below 5ppb.If the containing ratio of the dissolubility ferrum of divalent is to contain above-mentioned reducing agent in the aqueous solution containing hyaluronic acid or hyaluronate below 5ppb, the intrinsic viscosity residual rate after preserving significantly improves, and this is confirmed in embodiment described later.Therefore, according to this stabilisation promotion method, can significantly promote stable containing the aqueous solution of hyaluronic acid or hyaluronate.
In addition, according to the present invention, provide a kind of stabilizing agent, this stabilizing agent is for being the stabilized aqueous solution containing hyaluronic acid or hyaluronate below 5ppb by the containing ratio of the dissolubility ferrum of divalent, and described aqueous solution comprises the reducing agent that contains iodine.If the containing ratio of the dissolubility ferrum of divalent is to contain above-mentioned reducing agent in the aqueous solution containing hyaluronic acid or hyaluronate below 5ppb, the intrinsic viscosity residual rate after preserving significantly improves, and this is confirmed in embodiment described later.Therefore, at the containing ratio of the dissolubility ferrum of divalent, be while in the aqueous solution containing hyaluronic acid or hyaluronate below 5ppb, containing this stabilizing agent, can be significantly stable.
The invention effect
According to the present invention, the containing ratio of the dissolubility ferrum of divalent is below 5ppb, and comprises the reducing agent that contains iodine, so can access the aqueous solution containing hyaluronic acid or hyaluronate that stability is high.
The accompanying drawing explanation
Fig. 1 means the figure of the variation of the intrinsic viscosity residual rate while in the aqueous solution of the dissolubility ferrum that contains divalent and sodium iodide, adding the hyaluronate sodium powder.
The specific embodiment
Below, embodiments of the present invention are elaborated.Should illustrate, for fear of repeating identical content, suitably description thereof is omitted.
<containing the aqueous solution of hyaluronic acid or hyaluronate>
The aqueous solution containing hyaluronic acid or hyaluronate that an embodiment of the invention relate to, the containing ratio of the dissolubility ferrum of divalent is below 5ppb, comprises the reducing agent that contains iodine.For the aqueous solution containing hyaluronic acid or hyaluronate formed that forms by such, such as the embodiment described later confirmed, the intrinsic viscosity residual rate after preservation is high, the physical stability excellence.In addition, the reduction of viscosity and quality also is difficult for producing after long preservation or after the long-term time, for example, can be suitable for the raw material of pharmaceuticals, cosmetics, food etc.
As the above-mentioned reducing agent that contains iodine, for example, can be metal iodinated compounds class.As the metal iodinated compounds, for example, can exemplify sodium iodide, potassium iodide, calcium iodide or magnesium iodide.
Below above-mentioned 5ppb, for example, can be 0.001,0.01,0.1,0.5,1,2,4 or 5ppb.And this containing ratio is herein below illustrative value, or in the scope of any 2 values.For this containing ratio, this viewpoint from raising containing the stability of the aqueous solution of hyaluronic acid or hyaluronate, containing ratio is more few better.
The containing ratio of the above-mentioned reducing agent that the aqueous solution containing hyaluronic acid or hyaluronate of present embodiment is contained for example, can be 5,10,30,50,100,150,300,500,800,1000,1500,2000,5000 or 10000 μ g/mL.In addition, this containing ratio can be also in the scope of illustrative any 2 values herein.In addition, this viewpoint from further raising containing the stability of the aqueous solution of hyaluronic acid or hyaluronate, more than this containing ratio is preferably 10 μ g/mL, more preferably more than 100 μ g/mL.In addition, from the viewpoint that production cost reduces or operability improves, this containing ratio is preferably below 2000 μ g/mL, more preferably below 1500 μ g/mL.
The hyaluronate sodium that the aqueous solution containing hyaluronic acid or hyaluronate of present embodiment is contained or the mean molecule quantity of hyaluronate, for example, can be 500,000,800,000,1,000,000,1,500,000,1,800,000,2,000,000,2,500,000,3,000,000,5,000,000 or 8,000,000.This mean molecule quantity can be also in the scope of illustrative any 2 values herein.This viewpoint from further raising containing the viscosity of the aqueous solution of hyaluronic acid or hyaluronate, be preferably more than 1,000,000, more preferably more than 1,500,000.When the aqueous solution containing hyaluronic acid or hyaluronate that viscosity is high is treated the injection use of use as arthrosis, in the anelasticity excellence of affected part.Containing the aqueous solution of hyaluronic acid or hyaluronate, contained hyaluronic acid or the mean molecule quantity of hyaluronate are after measuring intrinsic viscosity, can adopt Laurent formula (LAURENT et al., Biochim Biophys Acta.1960Aug26; 42:476-485.) calculated.
The hyaluronic acid that the aqueous solution containing hyaluronic acid or hyaluronate of present embodiment is contained or the content of hyaluronate for example, can be 0.1,1,5,8,9,10,11,12,15 or 20mg/mL.This containing ratio can be also in the scope of illustrative any 2 values herein.The viewpoint of the operability during from therapeutic effect or for injection etc., preferably 5 with the scope of the value of 15mg/mL in, more preferably 8 with the scope of the value of 12mg/mL in.
The pH of the aqueous solution containing hyaluronic acid or hyaluronate of present embodiment for example, can be 5.5,6,6.5,6.8,7,7.8,8,8.5 or 9.This pH can be also in the scope of illustrative any 2 values herein.In addition, from the viewpoint of stability, this pH is preferably in the scope of 6.5 and 8 value, more preferably in the scope of 6.8 and 7.8 value.
The aqueous solution containing hyaluronic acid or hyaluronate of present embodiment can obtain by for example production method containing the aqueous solution of hyaluronic acid or hyaluronate, described production method comprise the dissolubility ferrum that will contain hyaluronic acid or hyaluronate and divalent compositions and, the reducing agent that contains iodine is dissolved in the operation in aqueous solution, and above-mentioned composition be take the containing ratio of dissolubility ferrum of the divalent in mode that the concentration of hyaluronic acid or hyaluronate the becomes 10mg/mL aqueous solution while being dissolved in aqueous solution below 5ppb.This production method does not need complicated operation, excellence aspect productivity or cost.
In this manual, so-called " hyaluronate " refers to, for example, can be hyaluronate sodium, potassium hyaluronate, Curiosin, calcium hyauronate, hyaluronic acid magnesium or hyaluronic acid ammonium.Wherein, from desirable viscosity or expect the viewpoint to arthropathic therapeutic effect, preferably clear matter acid sodium.The chemical name of hyaluronate sodium for example available [→ 3)-2-acetamido-2-deoxy-β-D-glucopyranosyl-(1 → 4)-β-D-sodium glucopyranosyluronate-(1 →] n(IUPAC) mean.
In this description, " the dissolubility ferrum of divalent " is in the dissolubility state and is the ferrum of divalent.Also available Fe
2+or divalent ferrum souvenir.
<medical composition etc.>
The aqueous solution containing hyaluronic acid or hyaluronate of present embodiment can be used as the raw material of medical composition.Now, the aqueous solution containing hyaluronic acid or hyaluronate that contains excellent in stability due to above-mentioned medical composition, so the viscosity and the quality that also are difficult for occurring after long preservation descend.In addition, for example, to intraarticular or its periphery, throw in the situation to medicament, can be detained for a long time or the desirable time at affected part.The agent shape of this medical composition is not particularly limited, and from affected part that can be to joint etc., directly throws the viewpoint to medicament, optimizing injection.As the container of injection, for example, can use syringe, cillin bottle or ampulla.Throwing during to medicament, can be thrown separately to medicament, still, preferably with the admissible one or more carrier of pharmacology or together mix with excipient, obtains utilizing the pharmaceutical preparation of any means manufacture of knowing in the technical field of galenic pharmacy and provides.This medical composition can with throw to the medicament form matchingly and buffer agent (for example, phosphate buffer, sodium acetate buffer), (for example releive agent, lidocaine hydrochloride, procaine hydrochloride etc.), stabilizing agent (for example, human serum albumin, Polyethylene Glycol etc.), the cooperation such as preservative agent (for example, benzyl alcohol, phenol etc.), antioxidant.In addition, this medical composition can contain dibastic sodium phosphate, crystallization sodium dihydrogen phosphate, the sodium chloride as additive.The medical composition be prepared from, for example, can throw to medicament people or mammal (such as rat, mice, rabbit, Canis familiaris L., monkey, sheep, pig, cattle, cat etc.).In addition, to comprise to prevent be the compositions that purpose is used to medical composition.
The throwing administration agent method of this medical composition can suitably be selected according to age of person under inspection, symptom, affected part etc.During for the treatment of morphotropism gonarthrosis, for example, the adult can be weekly 1 time, a 2.5mL, continuous 5 times to throwing to medicament in knee joint cavity.Perhaps, with symptom be maintained purpose the time, can throw to medicament with 2～4 weekly intervals.In addition, during for the treatment of scapulohumeral periarthritis, for example, the adult can be weekly 1 time, a 2.5mL, continuous 5 times to throwing to medicament in shoulder joint (shoulder joint chamber, the long tendon sheath of subacromial bursa or upper arm biceps tendon).In addition, during for the treatment of the knee-joint pain of rheumatoid arthritis, for example, the adult can be weekly 1 time, a 2.5mL, continuous 5 times to throwing to medicament in knee joint cavity.In addition, can and be used for suitable chemotherapy drugs throwing to medicament.
Pharmacological action as this medical composition, for example can enumerate following effect, , a) be combined viscoelasticity or the lubrication that covering surfaces causes with cartilaginous tissue because of hyaluronate, b) because of stable articular cartilage protective effect (the degeneration inhibitory action caused of cartilage matrix, repair etc.), c) because covering inflammatory cell and synovial cell's surface, or the analgesic activity caused because of generation inhibition of induced pain enhancing substance etc., perhaps d) synovial cell who the arthritis caused with following synovial membrane and cartilage degeneration is had to close relation, chondrocyte or neutrophilic granulocyte, the inflammatory cells such as macrophage bring impact and the effect of found inflammatory.By these effects, can expect to for example pain alleviate or activities of daily living, joint movable area are improved.
The aqueous solution containing hyaluronic acid or hyaluronate of present embodiment can be used as the raw material of cosmetic composition.Now, the aqueous solution containing hyaluronic acid or hyaluronate that above-mentioned cosmetic composition comprises excellent in stability, so viscosity and also difficult decline of quality after long preservation.In addition, while being used as Hydra cosmetic composition, moistening effect is easy to continue.
<stabilization method etc.>
The stabilisation promotion method of the aqueous solution containing hyaluronic acid or hyaluronate of other embodiments, the method comprise the dissolubility ferrum that will contain hyaluronic acid or hyaluronate and divalent compositions and, the reducing agent that contains iodine is dissolved in the operation of aqueous solution, and above-mentioned composition be take the containing ratio of the divalent dissolubility ferrum in mode that the concentration of hyaluronic acid or hyaluronate the becomes 10mg/mL aqueous solution while being dissolved in aqueous solution below 5ppb.According to the method, can access the aqueous solution containing hyaluronic acid or hyaluronate that physical stability is high.In addition, the method does not need complicated operation, the convenience excellence.
In addition, above-mentioned reducing agent can be used as the raw material containing the stabilizing agent of the aqueous solution of hyaluronic acid or hyaluronate.If use this stabilizing agent, the physical stability that the containing ratio that can improve the dissolubility ferrum of divalent is the following aqueous solution containing hyaluronic acid or hyaluronate of 5ppb.This stabilizing agent can be for Powdered or liquid.Can also contain buffer agent when in addition, liquid.
Above, embodiments of the present invention to be narrated, these are illustrations of the present invention, also can adopt above-mentioned various formations in addition.In addition, also can combine the formation that above-mentioned embodiment puts down in writing and adopt.
Embodiment
Below, further illustrate the present invention by embodiment, but the present invention is not limited to these.
<embodiment 1>
Adjust aqueous solution of sodium hyaluronate by following order.At first, after 1 liter of culture medium consisted of glucose 5%, potassium dihydrogen phosphate (potassium primary phosphate) 0.2%, polyprotein peptone (Polypeptone) 1.0%, yeast extract 0.5% is carried out to pasteurization, the micro-work of streptococcus equi (Streptococcus equi) FM-100(is ground to bar and posts No. 9027) inoculated.Limit passes into air with 1vvm, and limit, with 200 rev/mins of stirrings, is controlled in the mode of 33 ℃ of temperature, pH8.5(automatic dripping 20% sodium hydroxide) the lower cultivation 20 hours.After this solution is filtered with the antibacterial defecator, the hyaluronic acid solution that dialysis is reclaimed in dialyzer in 12 hours to water.In order to prevent sneaking into of ferrum, returnable is used the container that inner surface is glass system.Add wherein sodium chloride to become 2.5%, add the ethanol of 2 times of amounts of hyaluronic acid solution to make the hyaluronate sodium precipitation.By ethanol washing and precipitating 5 times, fully rinse after impurity under 40 ℃ air-dry 10 hours, obtain the powder of hyaluronate sodium.
Next, the hyaluronate sodium powder dissolution that obtains, in the aqueous solution that comprises 2mM phosphate buffer and 0.9% sodium chloride, is obtained comprising respectively 5,8,10,12, the aqueous solution of sodium hyaluronate of the hyaluronate sodium of 15mg/mL.And then, measure intrinsic viscosity, try to achieve the molecular weight of hyaluronate sodium with the Laurent formula, result is 2,530,000.
<comparative example 1>
Press the order of embodiment 1 record and cultivate streptococcus equi (Streptococcus equi) FM-100, with patent documentation 3(JP 2008-280430) embodiment 1 in the identical refining aqueous solution of sodium hyaluronate of order of the order of record.Particularly, at first, after 1 liter of culture medium consisted of glucose 5%, potassium dihydrogen phosphate 0.2%, polyprotein peptone 1.0%, yeast extract 0.5% is carried out to pasteurization, to streptococcus equi (Streptococcus equi), FM-100 is inoculated.Limit passes into air with 1vvm, and limit is with 200 rev/mins of stirrings, in the control of the automatic dripping of 33 ℃ of temperature, pH8.5(20% sodium hydroxide) the lower cultivation 20 hours.By 10 times of ion exchange water dilutions for culture fluid, process 1 hour to this 2.5L aqueous solution interpolation 5g active carbon (the white Heron RW50-T of military field drug company system), 30g perlite (ROKAHELP#409 of Mitsu Mining & Smelting Co., Ltd), filtered with buchner funnel.Repeatedly carry out 2 these operations and remove the organic principle in culture medium, adjust hyaluronate sodium and contain liquid.Next, to the chromatographic column of internal diameter 15mm, height 300mm, fill the Diaion CR11 processed of 68ml Mitsubishi Chemical Ind, make resin regeneration.With SV=18(1200ml/hr) pass into above-mentioned hyaluronate sodium to this chromatographic column and contain liquid 2.5L.The Sal of 2g is dissolved in to chromatographic column by liquid 1L, after being adjusted to pH7, is separated out with the 2-propanol, at 40 ℃ of lower vacuum dryings, obtain the powder of hyaluronate sodium.
Next, the hyaluronate sodium powder dissolution that obtains, in the aqueous solution that comprises 2mM phosphate buffer and 0.9% sodium chloride, is obtained comprising respectively 5,8,10,12, the aqueous solution of sodium hyaluronate of the hyaluronate sodium of 15mg/mL.And then, measure intrinsic viscosity, try to achieve the molecular weight of hyaluronate sodium with the Laurent formula, result is 2,400,000.
<evaluation Example 1>
(1) analysis of dissolubility ferrum
By the powder dissolution of hyaluronate sodium of preparation in embodiment 1 and comparative example 1, in the aqueous solution that comprises 2mM phosphate buffer and 0.9% sodium chloride, preparation contains 5,8,10,12 or the aqueous solution of sodium hyaluronate (No.1～10) of 15mg/mL hyaluronate sodium respectively.Next, to each aqueous solution with the dissolubility ferrum amount of dissolubility ferrum amount, divalent and 3 valencys of the sequential determination ferrum amount divalent of following (1-1)～(1-3) and total ferrum amount.The ferrum amount that total ferrum amount comprises dissolubility and indissolubility.The detectable limit of the dissolubility ferrum amount of dissolubility ferrum amount, divalent and 3 valencys of ferrum amount divalent and total ferrum amount is 5ppb.
(1-1) analytical method of the dissolubility ferrum of divalent
A) aqueous solution of sodium hyaluronate 2.75g is fetched in sample bottle.
B) add potassium thiocyanate solution 0.1mL, 1,10-o-phenanthroline solution 0.05mL also mixes.
C), after being diluted to about 10mL, place approximately 10 minutes.
D) after adding chloroform 5mL, airtight.Rock 5 minutes, extract.
E) after standing, take out 4mL chloroform phase, move to other sample bottle.
F) after evaporation drying is solidified on hot plate, add concentrated nitric acid 0.5mL to be decomposed.
G) add rare nitric acid (1+100) 2mL, dissolve remaining composition.
H) with the ICP luminesceence analysis, Fe is carried out quantitatively.
(1-2) analytical method of the dissolubility ferrum of divalent and 3 valencys
A) aqueous solution of sodium hyaluronate 2.75g is fetched in sample bottle.
B) add oxammonium hydrochloride. solution 0.2mL.
C) add 1,10-o-phenanthroline solution 0.2mL, potassium thiocyanate solution 0.5mL.
D), after being diluted to about 10mL, place approximately 10 minutes.
E) after adding 4-methyl-2 pentanone 5mL, airtight.Rock 1 minute, extract.
F) after standing, take out the 4-methyl-2 pentanone phase of 4mL, move to other sample bottle.
G) after evaporation drying is solidified on hot plate, add concentrated nitric acid 0.5mL to be decomposed.
H) add rare nitric acid (1+100) 2mL, dissolve remaining composition.
I) with the ICP luminesceence analysis, Fe is carried out quantitatively.
(1-3) analytical method of full ferrum
A) aqueous solution of sodium hyaluronate 2.75g is fetched in sample bottle.
B) adding HCl(1+1) 0.1mL heats with hot plate.
C) carry out the b in the analytical method of dissolubility ferrum of above-mentioned (1-2) divalent and 3 valencys) following operation.
(1-4) ferrum quantitative analysis result
The analysis result of above-mentioned (1-1)～(1-3) is shown in to table 1.
[table 1]
(2) characteristic viscosity determining
So that the hyaluronic acid na concn becomes the powder (No.11～12) that the mode of 10mg/mL is dissolved respectively the hyaluronate sodium of preparation in embodiment 1 or comparative example 1 in the aqueous solution that comprises 2mM phosphate buffer and 0.9% sodium chloride.And then, under 80 ℃, preserve after 24 hours, measure intrinsic viscosity and intrinsic viscosity residual rate (%), the results are shown in table 2.Should illustrate, the record that intrinsic viscosity is remedied viscosity one hurdle of " refining hyaluronate sodium " according to the 15 correction Pharmacopeia of Japan second is measured.
[table 2]
(the FeCl of iron chloride (II) shown in dissolving table 3 in the aqueous solution that comprises 2mM phosphate buffer and 0.9% sodium chloride
2) (No.13～19).Next, so that the hyaluronic acid na concn becomes the powder that the 10mg/mL mode is dissolved the hyaluronate sodium of preparation in embodiment 1 in each aqueous solution.And then, under 80 ℃, preserve after 24 hours, measure intrinsic viscosity and intrinsic viscosity residual rate (%).The results are shown in table 3.
[table 3]
(the FeCl of iron chloride (III) shown in dissolving table 4 in the aqueous solution that comprises 2mM phosphate buffer and 0.9% sodium chloride
3) (No.20～22).Next, so that the hyaluronic acid na concn becomes the powder that the 10mg/mL mode is dissolved the hyaluronate sodium of preparation in embodiment 1 in each aqueous solution.And then, under 80 ℃, preserve after 24 hours, measure intrinsic viscosity and intrinsic viscosity residual rate (%).The results are shown in table 4.
[table 4]
Known according to above result: 1) if use the method for embodiment 1 record, the mixed volume that can adjust the dissolubility ferrum of divalent is the following aqueous solution of sodium hyaluronate of 5ppb, 2) the dissolubility ferrum by divalent reduces the intrinsic viscosity after the preservation of aqueous solution of sodium hyaluronate, 3) the dissolubility ferrum of 3 valencys do not affect the intrinsic viscosity after the preservation of aqueous solution of sodium hyaluronate.
<evaluation Example 2>
Various additives shown in dissolving table 5 (No.23～34) in the aqueous solution that comprises 2mM phosphate buffer and 0.9% sodium chloride.Next, so that the hyaluronic acid na concn becomes the powder that the 10mg/mL mode is dissolved the hyaluronate sodium of preparation in embodiment 1 in each aqueous solution.And then, under 80 ℃, preserve after 24 hours, measure intrinsic viscosity and intrinsic viscosity residual rate (%).In above-mentioned additive, the compound that glycine (Glycine), L-Aspartic acid sodium, castor sugar are irreducibility.The compound that sodium iodide, potassium iodide, sodium bromide, sodium sulfite, sodium sulfide, sodium thioglycolate, glucose and ascorbic acid are reproducibility.
[table 5]
Additive
Sodium iodide: and the pure medicine of light company, 194-02272
Potassium iodide: and the pure medicine of light company, 168-03975
Glycine: and the pure medicine of light company, 036435
L-Aspartic acid sodium: and the pure medicine of light company, 193-01262
Sodium bromide: and the pure medicine of light company, 193-01505
Sodium sulfite: and the pure medicine of light company, 190-01375
Sodium sulfide: and the pure medicine of light company, 197-03362
Sodium thioglycolate: and the pure medicine of light company, 590-11762
Glucose: and the pure medicine of light company, 076-05705
Castor sugar (sucrose): and the pure medicine of light company, 196-13705
Sodium ascorbate: and the pure medicine of light company, 196-01252
From above result, contain sodium iodide or potassium iodide if be dissolved with the aqueous solution of the powder of the hyaluronate sodium of preparation in embodiment 1, improve the stability of aqueous solution of sodium hyaluronate.In addition, even identical with sodium iodide and potassium iodide, be also the compound with character of reproducibility, in the situation that add sodium sulfite, sodium sulfide, sodium thioglycolate, glucose and ascorbic acid, stability also reduces certainly.
<evaluation Example 3>
Various additives shown in dissolving table 6 (No.35～41) in the aqueous solution that comprises 2mM phosphate buffer and 0.9% sodium chloride.And then, add the dissolubility ferrum of 11.3ppb(as divalent in each aqueous solution, 5ppb) iron chloride (II).Next, so that the hyaluronic acid na concn becomes the powder that the 10mg/mL mode is dissolved the hyaluronate sodium of preparation in embodiment 1 in each aqueous solution., 80 ℃ under preserve 24 hour after, measure intrinsic viscosity and intrinsic viscosity residual rate (%) thereafter.
[table 6]
If by above result, the dissolubility ferrum of the divalent that the aqueous solution of the powder that is dissolved with hyaluronate sodium of preparation contains 5ppb is shown in embodiment 1, the stability of aqueous solution of sodium hyaluronate reduces.In addition, the reduction of known its stability is significantly suppressed because of sodium iodide or potassium iodide.
<evaluation Example 4>
Dissolve sodium iodide (No.42～48) with the concentration shown in table 7 in the aqueous solution that comprises 2mM phosphate buffer and 0.9% sodium chloride.Next, so that the hyaluronic acid na concn becomes the powder that the 10mg/mL mode is dissolved the hyaluronate sodium of preparation in embodiment 1 in each aqueous solution.And then, under 80 ℃, preserve after 24 hours, measure intrinsic viscosity and intrinsic viscosity residual rate (%).
[table 7]
Known according to above result, if in embodiment 1, the aqueous solution of the powder that is dissolved with hyaluronate sodium of preparation contains the above sodium iodide of 10 μ g/mL, the stability of aqueous solution of sodium hyaluronate improves.While in addition, containing 100 μ g/mL left and right sodium iodide, the raising of its stability slows down slowly.
<evaluation Example 5>
Dissolve sodium iodide so that its concentration becomes 1000 μ g/mL in the aqueous solution that comprises 2mM phosphate buffer and 0.9% sodium chloride.And then, add the iron chloride (II) (No.49～54) of the concentration shown in table 8 in each aqueous solution.Next, so that the hyaluronic acid na concn becomes the powder that the 10mg/mL mode is dissolved the hyaluronate sodium of preparation in embodiment 1 in each aqueous solution., 80 ℃ under preserve 24 hour after, measure intrinsic viscosity and intrinsic viscosity residual rate (%) thereafter.
[table 8]
The result of the result of table 8 and table 3 is depicted as to chart just as shown in Figure 1.Known according to this Fig. 1, if the sodium iodide that contains 1000 μ g/mL in the solutions of hyaluronan of the dissolubility concentration of iron that contains the low concentration divalent, the stability of aqueous solution of sodium hyaluronate improves.This stablizing effect particularly dissolubility concentration of iron of divalent is that 5ppb is remarkable when following.
As described above, the low aqueous solution of sodium hyaluronate of containing ratio of the dissolubility ferrum of divalent, the intrinsic viscosity residual rate after preservation improves.In addition, if contain sodium iodide in its aqueous solution of sodium hyaluronate, the intrinsic viscosity residual rate further improves.The stability of this aqueous solution of sodium hyaluronate is high, and after long preservation, the reduction of viscosity and quality also be difficult for to produce, therefore such as the raw material that is particularly suitable as medical composition etc.In addition, therefore also can suppress cost owing to being suitable for long preservation.
Above, based on embodiment, the present invention is described.This embodiment is illustration, and various variation and these variation can be arranged, and also in scope of the present invention, this is that those skilled in the art can understand.
Claims (12)
1. the aqueous solution containing hyaluronic acid or hyaluronate, wherein, the containing ratio of the dissolubility ferrum of divalent is below 5ppb, and comprises the reducing agent that contains iodine.
2. the aqueous solution containing hyaluronic acid or hyaluronate according to claim 1, wherein, the concentration of described hyaluronic acid or hyaluronate is 5～15mg/mL.
3. the aqueous solution containing hyaluronic acid or hyaluronate according to claim 1 and 2, wherein, the described reducing agent that contains iodine is metal iodinated compounds class.
4. according to the described aqueous solution containing hyaluronic acid or hyaluronate of any one in claim 1～3, wherein, the content of described reducing agent is 10～10000 μ g/mL.
5. according to the described aqueous solution containing hyaluronic acid or hyaluronate of any one in claim 1～4, wherein, the mean molecule quantity of described hyaluronic acid or hyaluronate is more than 1,000,000.
6. according to the described aqueous solution containing hyaluronic acid or hyaluronate of any one in claim 1～5, wherein, described hyaluronate is hyaluronate sodium.
7. a medical composition, it comprises the described aqueous solution containing hyaluronic acid or hyaluronate of any one in claim 1～6.
8. an arthrosis is treated and is used injection, and it comprises the described aqueous solution containing hyaluronic acid or hyaluronate of any one in claim 1～6.
9. a cosmetic composition, it comprises the described aqueous solution containing hyaluronic acid or hyaluronate of any one in claim 1～6.
10. the production method containing the aqueous solution of hyaluronic acid or hyaluronate, it comprises: will contain hyaluronic acid or hyaluronate and divalent dissolubility ferrum compositions and, the reducing agent that contains iodine is dissolved in the operation in aqueous solution, and described compositions is so that the containing ratio of the dissolubility ferrum of divalent that the concentration of hyaluronic acid or hyaluronate becomes the mode of 10mg/mL while being dissolved in aqueous solution, in aqueous solution is below 5ppb.
11. the stabilisation promotion method containing the aqueous solution of hyaluronic acid or hyaluronate, it comprises: will contain hyaluronic acid or hyaluronate and divalent dissolubility ferrum compositions and, the reducing agent that contains iodine is dissolved in the operation in aqueous solution, and described compositions is so that the containing ratio of the dissolubility ferrum of divalent that the concentration of hyaluronic acid or hyaluronate becomes the mode of 10mg/mL while being dissolved in aqueous solution, in aqueous solution is below 5ppb.
12. a stabilizing agent, its containing ratio for the dissolubility ferrum of stablizing divalent is the aqueous solution containing hyaluronic acid or hyaluronate below 5ppb, wherein, and the reducing agent that described stabilizer package contains iodine.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011045770 | 2011-03-02 | ||
| JP2011-045770 | 2011-03-02 | ||
| PCT/JP2012/055424 WO2012118191A1 (en) | 2011-03-02 | 2012-03-02 | Aqueous solution containing hyaluronic acid or salt thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103442719A true CN103442719A (en) | 2013-12-11 |
Family
ID=46758116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012800110602A Pending CN103442719A (en) | 2011-03-02 | 2012-03-02 | Aqueous solution containing hyaluronic acid or salt thereof |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP5957439B2 (en) |
| KR (1) | KR20140024863A (en) |
| CN (1) | CN103442719A (en) |
| WO (1) | WO2012118191A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021076076A1 (en) * | 2019-10-17 | 2021-04-22 | Betatech Medikal Cihazlar Sanayi Mumessillik Ic Ve Dis Ticaret Limited Sirketi | Cystitis solution comprising hyaluronic acid and polyethylene glycol and production method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10212303A (en) * | 1997-01-31 | 1998-08-11 | Denki Kagaku Kogyo Kk | Stabilizing composition for aqueous sodium hyaluronate solution |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1247175B (en) * | 1991-04-19 | 1994-12-12 | Fidia Spa | PROCEDURE FOR PURIFICATION OF HYALURONIC ACID AND FRACTION OF PURE HYALURONIC ACID FOR OPHTHALMIC USE. |
| JP2006104461A (en) * | 2004-09-10 | 2006-04-20 | Seikagaku Kogyo Co Ltd | Method for removing impurity in glycosaminoglycan fraction |
| US20090162905A1 (en) * | 2006-06-07 | 2009-06-25 | Hideki Murata | Method for Purification of Hyaluronic Acid Salt |
| JP2009011315A (en) * | 2007-06-05 | 2009-01-22 | Mitsubishi Rayon Co Ltd | Production method of hyaluronic acid |
-
2012
- 2012-03-02 WO PCT/JP2012/055424 patent/WO2012118191A1/en active Application Filing
- 2012-03-02 KR KR1020137026032A patent/KR20140024863A/en not_active Application Discontinuation
- 2012-03-02 JP JP2013502422A patent/JP5957439B2/en active Active
- 2012-03-02 CN CN2012800110602A patent/CN103442719A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10212303A (en) * | 1997-01-31 | 1998-08-11 | Denki Kagaku Kogyo Kk | Stabilizing composition for aqueous sodium hyaluronate solution |
Non-Patent Citations (1)
| Title |
|---|
| WONG,S.F. ET AL: "The role of superoxide and hydroxyl radicals in the degradation of hyaluronic acid induced by metal ions and by ascorbic acid", 《JOURNAL OF INORGANIC BIOCHEMISTRY》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012118191A1 (en) | 2012-09-07 |
| KR20140024863A (en) | 2014-03-03 |
| JP5957439B2 (en) | 2016-07-27 |
| JPWO2012118191A1 (en) | 2014-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH05503940A (en) | Novel insulin composition | |
| CN102238953A (en) | Injectable polydeoxyribonucleotide composition for the treatment of osteoarticular diseases | |
| JP3779200B2 (en) | Stabilized composition of aqueous solution of hyaluronic acid and / or salt thereof | |
| CN102740860B (en) | Read through inducer, and therapeutic agent for nonsense-mutation-type genetic diseases | |
| CN103442718A (en) | Aqueous solution containing hyaluronic acid or salt thereof | |
| CN103491967A (en) | Artificial saliva comprising hyaluronic acid | |
| RU2013157823A (en) | PHARMACEUTICAL COMPOSITIONS BASED ON SHK AND METHODS FOR PRODUCING AND USING THEM | |
| CN103547273A (en) | Pre-filled syringe filling syringe having resin barrel with aqueous solution containing hyaluronic acid or salt thereof | |
| CN103442719A (en) | Aqueous solution containing hyaluronic acid or salt thereof | |
| CN103442720A (en) | Aqueous solution containing hyaluronic acid or salt thereof | |
| CN103442721A (en) | Aqueous solution containing hyaluronic acid or salt thereof | |
| CN105435221B (en) | Pharmaceutical composition of humanized antibody for vascular endothelial growth factor | |
| EP3881841A1 (en) | Pharmaceutical composition | |
| EP2222312B1 (en) | Aqueous iron dextran preparation having one or more para-hydroxybenzoate compounds and/or salts thereof | |
| JP3917820B2 (en) | Ozagrel sodium-containing injection and method for stabilizing the same | |
| CN106389359A (en) | Belinostat medicine composition for injection and preparation method thereof | |
| FI98891C (en) | Procedure for raising the protein content in an aqueous solution | |
| CN102188367A (en) | Insulin glargine injecta and preparation method thereof | |
| CN104906127B (en) | A kind of PVP-I compound preparation of available iodine content stability enhancing and preparation method thereof | |
| CN101697973B (en) | Cefathiamidine preparation for injection and preparation method thereof | |
| CN105597087A (en) | Insulin glargine injection and preparation method thereof | |
| CN111991354A (en) | Compound amoxicillin powder and preparation method thereof | |
| RU2592975C1 (en) | METHOD OF PRODUCING COMPOSITIONS BASED ON HIGH-MOLECULAR HEPARIN WITH AMINO ACIDS AND 3-d METALS | |
| CN103405392B (en) | Special injection for sodium fusidate freeze-dried powder injection, and preparation method of special injection | |
| JP3236608B2 (en) | Stable aqueous solutions of bleomycins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20131211 |
|
| RJ01 | Rejection of invention patent application after publication |